A Phase 3 interventional study of ASC40 tablets and Placebo tablets in Recurrent Glioblastoma, sponsored by Ascletis Pharmaceuticals Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-31.
Sponsored by Ascletis Pharmaceuticals Co., Ltd. (part of Ascletis Pharma Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Glioblastoma with a site in China — 73 open to participants now, 80 under way, 7 of them phase 3. Glioblastoma · China.
Among the 142 studies in Glioblastoma with a site in China, this one is the 18th largest by enrollment of the 127 interventional ones that give a count, is one of 18 that started in 2022, is one of 11 in phase 3, reaches primary completion later than 15 of the 79 other live ones, and was the 57th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →73 of the 142 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:
Beijing Inno Medicine Co., Ltd. · Sites in China, United States
Ages 18–70
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Jecho Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Xiangya Hospital of Central South University · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 58 · Phase 3 13
First in 2008; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 36 across the 127 interventional studies, 100 across the 15 observational. Of the 21 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 142 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ascletis Pharmaceuticals Co., Ltd., one of the names counted as Ascletis Pharma Inc.. Under that name alone:
Ascletis Pharmaceuticals Co., Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Ascletis Pharma Inc. has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
15 of the studies in Glioblastoma with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07538128Huashan HospitalEvaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | 2026-11-27 |
| NCT06368934Huashan HospitalSub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma | 2026-12 |
| NCT05842746Peking Union Medical College HospitalElemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma | 2026-12 |
| NCT03005132Shanghai 10th People's HospitalIntegrative Analysis of Human Glioblastoma Multiforme | 2026-12 |
| NCT04959500Sun Yat-sen UniversityNewly Diagnosed Glioblastoma | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 142 studies in Glioblastoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASC40 tablets 100mg/m\^2 and bevacizumab 10mg/kg.
Drug: ASC40 tablets · Drug: Bevacizumab
Placebo and bevacizumab 10mg/kg.
Drug: Placebo tablets · Drug: Bevacizumab
ASC40 tablets administered orally once daily
Also known as: TVB-2640
Placebo administered orally once daily.
Bevacizumab once every 2 weeks, intravenous drip.
Progression-free survival
The time of progression or death from any cause in randomly grouped diseases (whichever comes first) was compared with the control group (evaluated by Independent Imaging Evaluation Committee \[IRC\])
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
Total survival
the time from random grouping to death, compared with the control group.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months
Objective remission rate
It is evaluated once in the 4th week after using experimental drugs (experimental drug group or control group), and then every 8 weeks until the disease progresses or dies (evaluated by \[IRC\]).
Time frame: Week 4 to Month 6 (every 8 weeks)
Started Jan 2022 (actual). Primary completion is estimated for Jun 2025, 41 months after the start.
Of 44 phase 3 interventional studies under Glioblastoma, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 87. This study's planned 41 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TVB-2640
Ascletis Pharmaceuticals Co., Ltd. →